-+ 0.00%
-+ 0.00%
-+ 0.00%
Revolution Medicines' Rasonque-Chemotherapy Combination Shows 60.7% Response Rate in Pancreatic Cancer Trial
Share
Listen to the news
Revolution Medicines' Rasonque-Chemotherapy Combination Shows 60.7% Response Rate in Pancreatic Cancer Trial
  • Revolution Medicines reported updated Phase 1/2 results showing durable tumor responses with RASONQUE combined with chemotherapy in previously untreated metastatic pancreatic cancer.
  • The combination's safety profile remained consistent with previously observed profiles for the treatments.
  • Findings support the ongoing Phase 3 RASolute 303 trial comparing RASONQUE alone or with chemotherapy against chemotherapy alone.
  • Results are scheduled for presentation at the ENA Symposium in Barcelona on November 20, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revolution Medicines Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611191805PRIMZONEFULLFEED9881815) on November 19, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending